

## **Septic Shock: A Genome-Wide Association Study and Polygenic Risk Score Analysis**

Shannon D'Urso\*, B.AdvSc (Hons).<sup>1</sup>

Dorrilyn Rajbhandari, PostGradDip (Clinical Nursing).<sup>2</sup>

Elizabeth Peach, MS.<sup>1</sup>

Erika de Guzman, BBsc (Human Genetics).<sup>3</sup>

Qiang Li, MSc.<sup>2</sup>

Sarah E. Medland, PhD.<sup>4</sup>

Scott D. Gordon, PhD.<sup>4</sup>

Nicholas G Martin, PhD.<sup>4</sup>

CHARGE Inflammation Working Group

Symen Ligthart, MD.<sup>5,6</sup>

Matthew A. Brown, FRACP.<sup>7</sup>

Joseph Powell, PhD.<sup>8</sup>

Colin McArthur, FCICM.<sup>9</sup>

Andrew Rhodes, MD.<sup>10</sup>

Jason Meyer, RN.<sup>2</sup>

Simon Finfer, FCICM.<sup>2</sup>

John Myburgh, DSc.<sup>2</sup>

Antje Blumenthal, Dr rer. nat.<sup>1</sup>

Jeremy Cohen, PhD.<sup>11, 12, 13</sup>

Balasubramanian Venkatesh\* \*\*, MD.<sup>2, 12, 13, 14</sup>

Gabriel Cuellar-Partida\*\*, PhD.<sup>1</sup>

David M. Evans\* \*\*, PhD.<sup>1, 15, 16</sup>

\* Joint corresponding author.

[s.durso@uq.edu.au](mailto:s.durso@uq.edu.au), Tel: +61 (0) 7 3443 7051, Fax: +61 (0) 7 3443 6966

Translational Research Institute, 37 Kent Street, Woolloongabba QLD 4102, AUSTRALIA,

\*\* Joint last authors

<sup>1</sup>The University of Queensland Diamantina Institute, University of Queensland, Brisbane, Queensland, Australia

<sup>2</sup>The George Institute for Global Health, Sydney, Australia

<sup>3</sup>Australian Translational Genomics Centre, Queensland University of Technology, Brisbane, Queensland, Australia

<sup>4</sup>QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

<sup>5</sup>Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands

<sup>6</sup>Department of Intensive Care, Erasmus University Medical Center, Rotterdam, the Netherlands

<sup>7</sup>Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane, Queensland, Australia

<sup>8</sup>Garvan-Weizmann Centre for Cellular Genomics, Garvan Institute, Sydney, Australia; UNSW Cellular Genomics Futures Institute, University of New South Wales, Sydney, Australia

<sup>9</sup>Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand

<sup>10</sup>Department of Adult Critical Care, St George's University Hospitals NHS Foundation Trust and St George's University of London, London, UK

<sup>11</sup>Royal Brisbane and Women's Hospital

<sup>12</sup>The Wesley Hospital

<sup>13</sup>University of Queensland, Brisbane,

<sup>14</sup>University of New South Wales, Sydney

<sup>15</sup>Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, UK

<sup>16</sup>Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

**Key words:** Genetic association study, genetic risk scores, sepsis, septic shock, genomics

## Abstract

Previous genetic association studies have failed to identify loci robustly associated with sepsis, and there have been no published genetic association studies or polygenic risk score analyses of patients with septic shock, despite evidence suggesting genetic factors may be involved. We systematically collected genotype and clinical outcome data in the context of a randomized controlled trial from patients with septic shock to enrich the presence of disease associated genetic variants. We performed genome-wide association studies of susceptibility and mortality in septic shock using 493 patients with septic shock and 2442 population controls, and polygenic risk score analysis to assess genetic overlap between septic shock risk/mortality with clinically relevant traits. One variant, rs9489328, located in *AL589740.1* non-coding RNA, was significantly associated with septic shock ( $p = 1.05 \times 10^{-10}$ ), however is likely a false-positive. We were unable to replicate variants previously reported to be associated ( $p < 1.00 \times 10^{-6}$  in previous scans) with susceptibility to, and mortality from sepsis. Polygenic risk scores for hematocrit and granulocyte count were negatively associated with 28-day mortality ( $p = 3.04 \times 10^{-3}$ ;  $p = 2.29 \times 10^{-3}$ ), and scores for C-reactive protein levels were positively associated with susceptibility to septic shock respectively ( $p = 1.44 \times 10^{-3}$ ). Results suggest common variants of large effect do not influence septic shock susceptibility, mortality, and resolution, however genetic predispositions to clinically relevant traits are significantly associated with increased susceptibility and mortality in septic individuals.

## **Background**

Sepsis is an abnormal host response to infection, resulting in organ and tissue damage (Singer et al., 2016). Septic shock is the most severe form of sepsis, with a significantly higher mortality rate due to profound circulatory and metabolic abnormalities (Singer et al., 2016). The annual worldwide incidence of sepsis in adults has been estimated at 31.5 million cases per year, of which 5.3 million instances are fatal (Fleischmann et al., 2016). Sepsis poses a high financial burden on the economy, with United States in-hospital costs for each episode averaging US\$22,100 (Angus et al., 2001).

Individuals vary widely in terms of their susceptibility to sepsis and their prognosis, and this heterogeneity is thought to be in part due to host genetic factors (Sørensen et al., 1988). A genetic basis for susceptibility to sepsis has long been suspected since epidemiological studies found that adopted individuals had markedly increased risk of mortality from infection when a biological parent had died prematurely from infection, but no corresponding increase risk in mortality when an adoptive parent had died from infection (Sørensen et al., 1988). However, previous candidate gene and genome-wide association studies (GWAS) of sepsis have had limited success in identifying genetic loci robustly associated with the disease and outcomes (Rautanen et al., 2015; Scherag et al., 2016; Srinivasan et al., 2017). This is possibly due to lack of statistical power caused by a combination of small sample sizes and heterogeneity of both the patient population and of the phenotype (Rautanen et al., 2015; Scherag et al., 2016; Srinivasan et al., 2017).

We designed the ADRENAL Genome-Wide Association Study (ADRENAL-GWAS) to investigate the genetic influences on susceptibility to, resolution of, and mortality from septic shock. We performed GWAS on a cohort of critically ill patients who were enrolled into a randomized controlled trial into the efficacy of corticosteroid therapy in septic shock

(ADRENAL) (Venkatesh et al., 2018). We sampled individuals suffering from septic shock, as opposed to sepsis, on the rationale that focusing on extreme cases will increase statistical power to detect genetic associations as has been done successfully in the case of many other diseases and complex traits (Barnett et al., 2013).

To improve our understanding of genetic basis of sepsis, we performed additional analyses with increased power to complement the knowledge gained from GWAS. These include gene and pathway based analysis and evaluation of polygenic risk scores. To our knowledge these approaches have not been used in the evaluation of sepsis or septic shock.

## **Methods**

### ***Study Participants***

The ADRENAL Genome-Wide Association Study (ADRENAL-GWAS) is a sub-study within the main ADRENAL trial (ClinicalTrials.gov number, NCT01448109) designed to investigate the genetics and genomics of septic shock. All ADRENAL participants who were admitted to 27 participating hospital sites in three countries (Australia, New Zealand, and the United Kingdom) were eligible for the ADRENAL-GWAS substudy. The inclusion/exclusion criteria were similar to the original ADRENAL study and summarised in Supplementary Methods S1 (Venkatesh et al., 2018). Blood samples from ADRENAL-GWAS participants (n = 578) were collected at the time of randomisation, prior to administration of corticosteroids/placebo. Blood was collected into 2 x 2.5 mL EDTA, 2 x 2.5 mL serum blood collection vacuettes (Interpath; Cat. No. 455071), and 1 x 2.5 mL PAXgene RNA Vacutainer (Becton Dickinson; Cat. No. 762165).

An unpublished genotyped cohort consisting of 3624 individuals collected at the QIMR Berghofer Medical Research Institute (QIMRB) was used as a control group in the case-control GWAS analyses. These unselected controls were drawn from the controls (i.e.

'healthy' individuals) used in studies of reproductive health or melanoma risk factors. DNA was extracted from either blood or saliva samples. Notably, the controls, while drawn from an unselected cohort, were deliberately chosen as they were genotyped using the same array, and had similar underlying ancestries to the ADRENAL participants.

### ***Genotyping and Quality Control***

ADRENAL-GWAS genomic DNA extractions were performed on 200 µl of whole blood using the QIASymphony SP instrument according to the manufacturer's protocol (QIASymphony DSP DNA Mini Kit, Cat. No. 937236). Genomic DNA was eluted in 100 µl of Buffer ATE and quantified using the Trinean Dropsense 96. Samples were genotyped on the Illumina Infinium Global Screening Array-24+ v1.0 (20005136). The arrays were scanned on an Illumina iScan system and the raw fluorescence intensity data was normalized and clustered for each sample using Illumina Genome Studio (v 2.0.3). Genotypes were called using the standard Illumina GSA-24v1-0\_A6 Cluster File.

In the QIMRB cohort, DNA was extracted from either blood or saliva samples, and genotyped using the Illumina Infinium Global Screening Array-24+ v1.0. Genotype data were screened for genotyping quality (GenCall < 0.7), single nucleotide polymorphism (SNP) and individual call rates (< 0.95), Hardy Weinberg Equilibrium (HWE) failure ( $P < 10^{-6}$ ), and minor allele frequency (MAF < 0.01). As these samples were genotyped in the context of a larger project, the data were integrated with the larger QIMRB genotype project and the data were checked for pedigree, sex and Mendelian errors, and for non-European ancestry.

The PLINK v1.90b3.31 software package was used to carry out a number of standard quality control (QC) procedures (Chang et al., 2015). A detailed breakdown of QC procedures can be found in the Supplementary Methods S3.

## ***Outcomes***

The primary outcome was death from any cause at 90 days, and the secondary outcomes were death at 28 days, shock resolution, and susceptibility to septic shock. For diagnostic criteria and definitions of these outcomes see Supplementary Methods S1 and Supplementary Methods S2.

## ***Statistical Power Analyses***

We investigated power to detect variants at genome-wide levels of significance ( $\alpha = 5 \times 10^{-8}$ ) and also power to replicate variants reported in previous genome-wide association studies of susceptibility to sepsis and 28-day mortality ( $\alpha = 0.05$ ) using the Genetic Association Study Power Calculator (Johnson & Abecasis, 2017). The relationship between heterozygous relative risk (RR; a measure of genetic effect size) and statistical power is presented in the Supplementary Methods S4. We assumed a lifetime risk of septic shock of 1%, a multiplicative model of disease risk (on the odds scale), that the risk locus had been genotyped ( $r^2 = 1$ ), and we matched the GWAS sample sizes (see Supplementary Methods S4).

The susceptibility to septic shock GWAS had the most statistical power of all the GWAS, where for genome-wide association analyses ( $\alpha = 5 \times 10^{-8}$ ), we expect 80% power to detect variants with a heterozygous RR of 1.55 and 2.52 for a risk allele frequency of 0.50 and 0.05 respectively. For replication of previous findings ( $\alpha = 0.05$ ), there is 80% power to detect variants with a heterozygous RR of 1.22 and 1254 for a risk allele frequency of 0.50 and 0.05 respectively. Power calculations for the other analyses are presented in Supplementary Figure S3.

### ***Genome-Wide Association Analyses***

We performed logistic regression analysis assuming an underlying additive genetic model (on the log scale) as implemented in PLINK across the genome on septic shock patients (ADRENAL-GWAS) and healthy controls (QIMRB). The first five principal components (PCs) from a PC analysis of the cleaned merged GWAS dataset were used as covariates. Further, we performed logistic regression analysis, on ADRENAL-GWAS participants only (no controls), assuming an underlying additive genetic model using PLINK for 28-day mortality, 90-day mortality, and shock resolution. Covariates included sex and the first five PCs.

### ***Look Up of Previously Reported Variants***

Suggestive associations ( $p \leq 1 \times 10^{-5}$ ) reported in analyses of 28-day survival/mortality in sepsis (Rautanen et al. survivors = 1194, non-survivors = 359; Scherag et al. survivors = 2803, non-survivors = 667) were queried in our 28-day mortality GWAS summary statistics (Rautanen et al., 2015; Scherag et al., 2016). Likewise, SNPs that reached suggestive significance in a susceptibility GWAS of premature infants (Srinivasan et al. cases = 351, controls = 406) and two GWAS from the UK Biobank (UKBB) were also queried in our susceptibility to septic shock GWAS summary statistics (Sudlow et al., 2015; Srinivasan et al., 2017; Neale, 2018). The UKBB analyses were originally performed on cohorts defined as having 'other septicaemia' (Phecode\_A41, cases = 1096, controls = 360,098) and 'septicaemia/sepsis' (Phecode\_20002\_1657, cases = 238, controls = 360,956).



### ***Gene- and Pathway-Based Analyses***

A number of gene-/pathway-based analyses were performed on the GWAS data for each outcome to identify genes or pathways which were enriched through combining statistical information across many markers within a gene, or within multiple genes in a pathway, and testing for association with the outcome. The Complex-Traits Genetics Virtual Lab (CTG-VL) implemented version of FastBAT was used to perform gene-based association analyses on the summary level results (Bakshi et al., 2016; Cuéllar-Partida et al., 2019). Data-Driven Expression-Prioritized Integration for Complex Traits (DEPICT v.1 beta) was used to identify enriched genes, gene-sets/pathways, and cell/tissue types from independent lead variants ( $r^2 = 0.2$ ,  $MAF > 0.05$ , clump-kb 1000), which reached suggestive significance ( $p \leq 1 \times 10^{-5}$ ) (Pers et al., 2015).

### ***Polygenic Risk Score Analyses***

We downloaded GWAS summary-statistics for phenotypes with suspected shared genetic aetiology with sepsis, or requested the data from the authors (Sudlow et al., 2015; Zheng et al., 2017; Neale, 2019). These included large-scale GWAS meta-analyses for hematocrit, diastolic blood pressure (DBP), granulocyte count, white blood cell count (WBC), coronary artery disease, type-2 diabetes (T2D), C-reactive protein levels (CRP), ‘septicaemia/sepsis’ (Phecode\_20002\_1657), and ‘other septicaemia’ (Phecode\_A41) (International Consortium for Blood Pressure Genome-Wide Association Studies et al., 2011; Sudlow et al., 2015; Astle et al., 2016; Scott et al., 2017; Ligthart et al., 2018). Polygenic risk scores (PRS) for height were also constructed as a negative control (Yengo et al., 2018). Independent SNP signals from each set of summary statistics were identified using PLINK ( $r^2 = 0.1$ , clump-kb = 1000).

Genome-wide PRS for each of the above diseases/traits were generated for the 493 septic shock cases as well as for the 2442 control individuals that passed QC. Individuals were

scored on the number of risk alleles they carried for each variant (at the thresholds  $p < 5 \times 10^{-8}$ ,  $5 \times 10^{-6}$ , 0.01, 0.5, 1), weighted by regression coefficients from the respective GWAS (Evans et al., 2013). To investigate relationships between septic shock and the various traits, 28-day mortality was regressed on the PRS generated for each septic shock individual using logistic regression, with age, sex, and the first five PCs from the GWAS as covariates. Disease status (logistic regression) was regressed against the scores generated for the case/control cohort, with the first five PCs used as covariates.

## Results

From May 2014 through April 2017, 578 patients were enrolled into the GWAS sub-study at 27 hospital sites. The Intensive care units were in Australia (18 sites), New Zealand (4), and the United Kingdom (5). Of the 578 patients enrolled, 300 were assigned to receive hydrocortisone and 278 to receive placebo. A total of 493 septic shock cases passed QC, and of the 3624 QIMRB controls, 2442 individuals passed (Supplementary Methods S3). All individuals passing QC were of European descent (Supplementary Figure S1). A breakdown of the outcomes, sample sizes, and characteristics in ADRENAL-GWAS cases and QIMRB controls can be found in **Error! Reference source not found.** Treatment had no significant effect on 90-day mortality, 28-day mortality or shock resolution ( $p = 0.35, 0.62, 0.09$ ) and therefore had no confounding effect on the GWAS. GWAS were performed for all outcomes, however we focussed the latter analyses on 28-day mortality and susceptibility to septic shock to replicate past GWAS of sepsis, to be consistent, and reduce the burden of multiple testing correction.

{TABLE 1 ABOUT HERE}

### ***Genome-Wide Association Studies***

GWAS were performed for susceptibility to shock (493 cases, 2442 controls), 28-day mortality (90 non-survivors, 403 survivors), 90-day mortality (112 non-survivors, 381 survivors) and shock resolution (34 unresolved, 459 resolved). The Manhattan plots for each GWAS are presented in Figure 1. The T allele of the genotyped SNP rs9489328, was the only genetic variant to be significantly associated with any of the outcomes. This SNP sits within a non-coding RNA gene AL589740.1 (Supplementary Figure S4), and was associated with decreased risk of septic shock ( $p = 1.05 \times 10^{-10}$ ) (Table 2). Three genetic variants, rs11167801, rs7698838, and rs17128291, were associated with shock resolution at suggestive levels of significance ( $p < 1 \times 10^{-6}$ ). Quantile-Quantile plots (Supplementary Figure S5) and genomic inflation factors (Supplementary Table S2) suggest that the GWAS results were not systematically inflated.

{TABLE 2 ABOUT HERE}

[INSERT FIG 1 HERE]

**Figure 1.** Manhattan plots for (A) Susceptibility to Septic Shock, (B) 28-Day Mortality, (C) 90-Day Mortality, and (D) Resolution of Shock Genome-Wide Association Studies. Plots were generated using the Complex-Traits Genetics Virtual Lab (Cuéllar-Partida et al., 2019). The blue dotted line denotes the ‘suggestive significance’ threshold of  $p < 1 \times 10^{-6}$ , and the red line denotes the ‘genome-wide significance’ threshold of  $p < 5 \times 10^{-8}$ , and the lead single nucleotide polymorphisms surpassing these thresholds are annotated. Only genetic variants with a minor allele frequency greater than 5% are shown.

### ***Replication studies***

This study failed to replicate ( $p < 0.05$ ) any SNPs previously associated ( $p \leq 1 \times 10^{-5}$ ) with 28-day sepsis mortality/survival and susceptibility to sepsis (Supplementary Table S3 and Supplementary Table S4). SNPs that reached suggestive significance ( $p \leq 1 \times 10^{-5}$ ) from the UKBB sepsis related phenotypes also failed to replicate in the present septic shock GWAS (Supplementary Table S4) (Rautanen et al., 2015; Scherag et al., 2016; Srinivasan et al., 2017; Neale, 2018).

### ***Gene- and Pathway-Based Analyses***

The top five gene associations from FastBAT analyses for each outcome are summarised in Table 3. No genes reached the significance threshold ( $p \leq 2.5 \times 10^{-6}$ ). DEPICT did not identify any genes, pathways, cells or tissue types to be significantly enriched across all the GWAS at false discovery rate  $< 5\%$ , however the top five genes, pathways, and tissues can be found in Supplementary Table S5, Supplementary Table S6 and Supplementary Table S7.

{TABLE 3 ABOUT HERE}

### ***Polygenic Risk Score Analysis***

PRS derived from GWAS summary statistics for ten different traits were calculated in the septic shock 28 day survivors and non-survivors, as well as in all septic shock patients and controls (Table ). The p-value threshold for statistical significance after Bonferroni correction for multiple testing is  $5.0 \times 10^{-3}$  (ten phenotypes). There were three significantly associated PRS in the expected direction. PRS for higher hematocrit and granulocyte count were negatively associated with 28-day mortality ( $p = 3.04 \times 10^{-3}$  and  $2.29 \times 10^{-3}$ ). PRS for higher CRP levels were positively associated with susceptibility to septic shock ( $p = 1.44 \times 10^{-3}$ ). For

all significant phenotypes, PRS constructed using SNPs that reached the less conservative p-value thresholds were more predictive than PRS constructed using only SNPs that met more conservative thresholds. There were no significant associations with the negative control height.

{TABLE 4 ABOUT HERE}

## **Discussion**

The current study presents, to our knowledge, the first report of genetic association analyses and the use of a polygenic risk score analytical approach in an exclusive cohort of patients with septic shock. The robust clinical outcome data was collected systematically in the context of a randomized controlled trial, and the analyses focused on patient centered outcomes. Comparable genetic studies consist only of small cohorts of patients with sepsis (Rautanen et al., 2015; Scherag et al., 2016; Srinivasan et al., 2017). We attempted to increase the power of the present study by focusing our efforts on the most severe form of sepsis, septic shock, which may involve alleles of larger effect. Additionally, we performed a suite of gene-based, pathway-based, and polygenic score analyses which have greater statistical power than single locus tests of association.

One SNP, rs9489328, was genome-wide significantly associated with susceptibility to septic shock. The rs9489328 SNP lies physically within an uncharacterised non-coding RNA (*AL589740.1*), with no known biological functions. This variant has not been previously significantly associated with any traits. The SNPs that are in linkage disequilibrium with it are not associated with the phenotype (Supplementary Table S8), hence the lack of ‘peak’ typical of true associations. Although rs9489328 passed all QC steps, it is possible that the association reflects a false positive and may be a genotyping artefact or a product of batch effects and should be validated with methods such as minisequencing or Taqman. A

discussion of the four SNPs, rs368584, rs11167801, rs7698838, and rs17128291, which reached suggestive levels of significance can be found in the Supplementary Discussion S1. The results from the present GWAS have not identified common variants of large effect contributing to susceptibility to, mortality from, and resolution of septic shock.

Despite being adequately powered, we failed to replicate previous SNP associations (which were notably rare variants; see Supplementary Table S3 and Supplementary Table S4) with sepsis in this study. This could be due to variability in the phenotype definitions, although this may be unlikely considering the variants contributing to the sepsis phenotype would likely be enriched in a cohort of septic shock individuals. Additionally, the previous studies used controls who had been exposed to sepsis risk factors, while this is ideal, we consider the reduction in power we experienced due to using population controls to be minimal given the low incidence of sepsis in the population (and likely in our controls)- and not the reason we were unable to replicate previous findings. Instead, the genetic variants prioritised in previous sepsis GWAS may be spurious associations arising from small cohort sizes.

Gene-based analyses failed to identify any genes significantly associated with the tested phenotypes. However, the top results for each analysis consisted of a number of cardiovascular and immune related genes. Variants within *KLB*, *NINJ2*, and *SSI8* have been previously associated with cardiovascular related phenotypes (Ikram et al., 2009; Astle et al., 2016; Kanai et al., 2018; Giri et al., 2019; Kichaev et al., 2019). Likewise, *NINJ2* and *CMTM7* have been associated with immune phenotypes (Astle et al., 2016; Jonsson et al., 2017). Given the previous associations of variants within these genes with cardiovascular and immune disorders, and observed increased risk of sepsis in individuals with chronic medical conditions, a connection with the pathophysiology of septic shock and may be biologically plausible, and may provide possible therapeutic targets given replication and functional follow-up (Wang et al., 2012).

This study was the first to conduct PRS analyses in a cohort of patients with septic shock and the results indicate that correlation between septic shock and a number of clinically relevant phenotypes are not only observed at the phenotypic level, as seen in observational studies, but are also reflected at the genetic level. Future Mendelian randomization analyses in larger genetic cohorts may help ascertain whether the PRS associations reflect a genetic overlap or a causal relationship (Davey Smith & Ebrahim, 2003). This may overcome confounding if the assumptions are met, and may provide valid targets for therapeutics.

The PRS analyses found increased CRP levels were predictive of increased susceptibility to septic shock. CRP is an acute-phase protein synthesised predominantly by liver cells in response to inflammatory cytokines, mainly interleukin 6, and therefore levels rise during inflammation (Ligthart et al., 2018). One interpretation of a significant association between PRS for CRP and septic shock is that increased CRP levels are causally related to an increased risk of septic shock. However, we consider this explanation unlikely to be true, because PRS from the most strongly CRP associated SNPs (i.e. PRS consisting of only genome-wide significant variants for CRP) were not associated with septic shock, despite previous research showing genome-wide significant SNPs explain more variance in CRP levels than PRS including SNPs reaching less stringent thresholds (Ligthart et al., 2018; Evans et al., 2013). More likely, the result could reflect a genetic overlap with potential underlying genetic inflammatory disorders which contribute to increased circulating CRP levels, and also increased risk of septic shock (Muller et al., 2005; Wang et al., 2012). For example, individuals with a genetic predisposition to increased CRP levels (likely actually reflecting underlying genetic inflammatory disorders which increase CRP levels) may respond to a severe infection with a more pronounced inflammatory response, resulting in progression into shock.

PRS for granulocyte count were negatively associated with 28-day mortality. The direction of the association suggests a genetic predisposition to higher granulocyte count is associated with decreased patient mortality, possibly because of a better immune response and successful clearing of the infection, which is supported in the literature (Bermejo-Martín et al., 2014).

PRS for decreased hematocrit levels were associated with increased 28-day mortality. Although the primary role of red blood cells is the transport of oxygen, they also mediate innate immunity through binding chemokines, pathogens, and nucleic acids (Anderson et al 2018). Sepsis patients present with high hematocrit due to capillary leak syndrome, and this could be related to an adverse outcome (van Beest et al., 2008). However the PRS reflect hematocrit in “healthy” individuals, and due to their immune role, a genetic predisposition to decreased red blood cell count (and thus lower hematocrit), could alter the host’s ability to mount an effective immune response.

The main limitation of the present study was a lack of statistical power primarily due to small sample size caused by the logistical difficulty of collecting biological samples in intensive care settings in a timely manner from a large number of sepsis patients. Additionally, power may have been reduced due to disease heterogeneity and misclassification bias. As sepsis is triggered by an environmental cue (i.e. infection), it is possible that some controls would in fact have been cases had they been exposed to the relevant environment, or may have already survived a sepsis episode, however this reduction in power is small given the low incidence of sepsis. Whilst we were underpowered to detect loci of small effect at genome-wide levels of significance, our results show common variants of large effect (e.g. variants in the major histocompatibility region which are known to contribute to many immune mediated diseases) do not contribute to susceptibility to or mortality from septic shock (Evans et al., 2011).



Although extensive molecular studies into sepsis and septic shock have been performed, genetic analyses have been limited despite longstanding evidence of a strong genetic component to the disease.

Sepsis is likely a complex trait, and hence will be influenced by many genetic variants with small effect. A large meta-analysis would be better powered to detect genetic variants with smaller effects that likely contribute to septic shock mortality/susceptibility, and may permit calculations using LD score regression, and place a lower bound on sepsis heritability (Bulik-Sullivan et al., 2015).

In conclusion, our polygenic risk score analyses identified several associations between genetic risk scores for clinically relevant variables and septic shock indicating shared underlying genetic aetiology with comorbid traits. This report in an exclusive cohort of patients with established septic shock represents a key step in understanding the genetic basis of septic shock and may inform the debate on future therapeutic targets for the condition.

Supplementary Material is available on the Cambridge Core website.

## References

- Anderson, H. L., Brodsky, I. E., & Mangalmurti, N. S. (2018). The Evolving Erythrocyte: Red Blood Cells as Modulators of Innate Immunity. *Journal of immunology*, 201(5), 1343–1351. <https://doi.org/10.4049/jimmunol.1800565>
- Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., & Pinsky, M. R. (2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Critical care medicine*, 29(7), 1303–1310. <https://doi.org/10.1097/00003246-200107000-00002>
- Astle, W. J., Elding, H., Jiang, T., Allen, D., Ruklisa, D., Mann, A. L., Mead, D., Bouman, H., Riveros-Mckay, F., Kostadima, M. A., Lambourne, J. J., Sivapalaratnam, S., Downes, K., Kundu, K., Bomba, L., Berentsen, K., Bradley, J. R., Daugherty, L. C., Delaneau, O., Freson, K., ... Soranzo, N. (2016). The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. *Cell*, 167(5), 1415–1429.e19. <https://doi.org/10.1016/j.cell.2016.10.042>
- Bakshi, A., Zhu, Z., Vinkhuyzen, A. A., Hill, W. D., McRae, A. F., Visscher, P. M., & Yang, J. (2016). Fast set-based association analysis using summary data from GWAS identifies novel gene loci for human complex traits. *Scientific reports*, 6, 32894. <https://doi.org/10.1038/srep32894>
- Barnett, I. J., Lee, S., & Lin, X. (2013). Detecting rare variant effects using extreme phenotype sampling in sequencing association studies. *Genetic epidemiology*, 37(2), 142–151. <https://doi.org/10.1002/gepi.21699>
- Bermejo-Martín, J. F., Tamayo, E., Ruiz, G., Andaluz-Ojeda, D., Herrán-Monge, R., Muriel-Bombín, A., Fe Muñoz, M., Heredia-Rodríguez, M., Citores, R., Gómez-Herrerías, J., Blanco,

J., & EXPRESS (Expresión Génica en Sepsis) and GRECIA (Grupo de Estudios y Análisis en Cuidados Intensivos) groups (2014). Circulating neutrophil counts and mortality in septic shock. *Critical care*, 18(1), 407. <https://doi.org/10.1186/cc13728>

Bulik-Sullivan, B. K., Loh, P. R., Finucane, H. K., Ripke, S., Yang, J., Schizophrenia Working Group of the Psychiatric Genomics Consortium, Patterson, N., Daly, M. J., Price, A. L., & Neale, B. M. (2015). LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature genetics*, 47(3), 291–295. <https://doi.org/10.1038/ng.3211>

Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015). Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience*, 4, 7. <https://doi.org/10.1186/s13742-015-0047-8>

Cuéllar-Partida, G., Lundberg, M., Fang Kho, P., D'Urso, S., Gutiérrez-Mondragón, L. F., Thanh Ngo, T., Hwang, L-D. (2019). Complex-Traits Genetics Virtual Lab: A community-driven web platform for post-GWAS analyses. *bioRxiv*, 518027. <https://doi.org/10.1101/518027>

Davey Smith, G., & Ebrahim, S. (2003). 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *International journal of epidemiology*, 32(1), 1–22. <https://doi.org/10.1093/ije/dyg070>

Evans, D. M., Brion, M. J., Paternoster, L., Kemp, J. P., McMahon, G., Munafò, M., Whitfield, J. B., Medland, S. E., Montgomery, G. W., GIANT Consortium, CRP Consortium, TAG Consortium, Timpson, N. J., St Pourcain, B., Lawlor, D. A., Martin, N. G., Dehghan, A., Hirschhorn, J., & Smith, G. D. (2013). Mining the human phenome using allelic scores that index biological intermediates. *PLoS genetics*, 9(10), e1003919. <https://doi.org/10.1371/journal.pgen.1003919>

Evans, D. M., Spencer, C. C., Pointon, J. J., Su, Z., Harvey, D., Kochan, G., Oppermann, U., Dilthey, A., Pirinen, M., Stone, M. A., Appleton, L., Moutsianas, L., Leslie, S., Wordsworth, T., Kenna, T. J., Karaderi, T., Thomas, G. P., Ward, M. M., Weisman, M. H., Farrar, C., ... Wellcome Trust Case Control Consortium 2 (WTCCC2) (2011). Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nature genetics*, 43(8), 761–767.

<https://doi.org/10.1038/ng.873>

Fleischmann, C., Scherag, A., Adhikari, N. K., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., Reinhart, K., & International Forum of Acute Care Trialists (2016). Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. *American journal of respiratory and critical care medicine*, 193(3), 259–272.

<https://doi.org/10.1164/rccm.201504-0781OC>

Giri, A., Hellwege, J. N., Keaton, J. M., Park, J., Qiu, C., Warren, H. R., Torstenson, E. S., Kovesdy, C. P., Sun, Y. V., Wilson, O. D., Robinson-Cohen, C., Roumie, C. L., Chung, C. P., Birdwell, K. A., Damrauer, S. M., DuVall, S. L., Klarin, D., Cho, K., Wang, Y., Evangelou, E., ... Edwards, T. L. (2019). Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. *Nature genetics*, 51(1), 51–62. [https://doi.org/10.1038/s41588-](https://doi.org/10.1038/s41588-018-0303-9)

[018-0303-9](https://doi.org/10.1038/s41588-018-0303-9)

Ikram, M. A., Seshadri, S., Bis, J. C., Fornage, M., DeStefano, A. L., Aulchenko, Y. S., Debette, S., Lumley, T., Folsom, A. R., van den Herik, E. G., Bos, M. J., Beiser, A., Cushman, M., Launer, L. J., Shahar, E., Struchalin, M., Du, Y., Glazer, N. L., Rosamond, W. D., Rivadeneira, F., ... Wolf, P. A. (2009). Genomewide association studies of stroke. *The New England journal of medicine*, 360(17), 1718–1728.

<https://doi.org/10.1056/NEJMoa0900094>

International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret, G. B., Munroe, P. B., Rice, K. M., Bochud, M., Johnson, A. D., Chasman, D. I., Smith, A. V., Tobin, M. D., Verwoert, G. C., Hwang, S. J., Pihur, V., Vollenweider, P., O'Reilly, P. F., Amin, N., Bragg-Gresham, J. L., Teumer, A., Glazer, N. L., Launer, L., Zhao, J. H., ... Johnson, T. (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*, 478(7367), 103–109. <https://doi.org/10.1038/nature10405>

Johnson J. L., Abecasis G. R. (2017). GAS Power Calculator: web-based power calculator for genetic association studies. *bioRxiv*, 164343. <https://doi.org/10.1101/164343>

Jonsson, S., Sveinbjornsson, G., de Lapuente Portilla, A. L., Swaminathan, B., Plomp, R., Dekkers, G., Ajore, R., Ali, M., Bentlage, A., Elmér, E., Eyjolfsson, G. I., Gudjonsson, S. A., Gullberg, U., Gylfason, A., Halldorsson, B. V., Hansson, M., Holm, H., Johansson, Å., Johnsson, E., Jonasdottir, A., ... Stefansson, K. (2017). Identification of sequence variants influencing immunoglobulin levels. *Nature genetics*, 49(8), 1182–1191. <https://doi.org/10.1038/ng.3897>

Kanai, M., Akiyama, M., Takahashi, A., Matoba, N., Momozawa, Y., Ikeda, M., Iwata, N., Ikegawa, S., Hirata, M., Matsuda, K., Kubo, M., Okada, Y., & Kamatani, Y. (2018). Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. *Nature genetics*, 50(3), 390–400. <https://doi.org/10.1038/s41588-018-0047-6>

Kichaev, G., Bhatia, G., Loh, P. R., Gazal, S., Burch, K., Freund, M. K., Schoech, A., Pasaniuc, B., & Price, A. L. (2019). Leveraging Polygenic Functional Enrichment to Improve GWAS Power. *American journal of human genetics*, 104(1), 65–75. <https://doi.org/10.1016/j.ajhg.2018.11.008>

Ligthart, S., Vaez, A., Võsa, U., Stathopoulou, M. G., de Vries, P. S., Prins, B. P., Van der Most, P. J., Tanaka, T., Naderi, E., Rose, L. M., Wu, Y., Karlsson, R., Barbalic, M., Lin, H.,

Pool, R., Zhu, G., Macé, A., Sidore, C., Trompet, S., Mangino, M., ... Alizadeh, B. Z. (2018). Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. *American journal of human genetics*, 103(5), 691–706. <https://doi.org/10.1016/j.ajhg.2018.09.009>

MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H., McMahon, A., Milano, A., Morales, J., Pendlington, Z. M., Welter, D., Burdett, T., Hindorff, L., Flicek, P., Cunningham, F., & Parkinson, H. (2017). The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). *Nucleic acids research*, 45(D1), D896–D901. <https://doi.org/10.1093/nar/gkw1133>

Muller, L. M., Gorter, K. J., Hak, E., Goudzwaard, W. L., Schellevis, F. G., Hoepelman, A. I., & Rutten, G. E. (2005). Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 41(3), 281–288. <https://doi.org/10.1086/431587>

Neale B. M. (2018). UK Biobank GWAS Round 2 Results [Internet]. Available from: [www.nealelab.is/uk-biobank/](http://www.nealelab.is/uk-biobank/)

Pers, T. H., Karjalainen, J. M., Chan, Y., Westra, H. J., Wood, A. R., Yang, J., Lui, J. C., Vedantam, S., Gustafsson, S., Esko, T., Frayling, T., Speliotes, E. K., Genetic Investigation of ANthropometric Traits (GIANT) Consortium, Boehnke, M., Raychaudhuri, S., Fehrmann, R. S., Hirschhorn, J. N., & Franke, L. (2015). Biological interpretation of genome-wide association studies using predicted gene functions. *Nature communications*, 6, 5890. <https://doi.org/10.1038/ncomms6890>

Rautanen, A., Mills, T. C., Gordon, A. C., Hutton, P., Steffens, M., Nuamah, R., Chiche, J. D., Parks, T., Chapman, S. J., Davenport, E. E., Elliott, K. S., Bion, J., Lichtner, P., Meitinger, T., Wienker, T. F., Caulfield, M. J., Mein, C., Bloos, F., Bobek, I., Cotogni, P., ...

ESICM/ECCRN GenOSept Investigators (2015). Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. *The Lancet. Respiratory medicine*, 3(1), 53–60. [https://doi.org/10.1016/S2213-2600\(14\)70290-5](https://doi.org/10.1016/S2213-2600(14)70290-5)

Scherag, A., Schöneweck, F., Kesselmeier, M., Taudien, S., Platzer, M., Felder, M., Sponholz, C., Rautanen, A., Hill, A., Hinds, C. J., Hossain, H., Suttorp, N., Kurzai, O., Slevogt, H., Giamarellos-Bourboulis, E. J., Armaganidis, A., Trips, E., Scholz, M., & Brunkhorst, F. M. (2016). Genetic Factors of the Disease Course after Sepsis: A Genome-Wide Study for 28Day Mortality. *EBioMedicine*, 12, 239–246. <https://doi.org/10.1016/j.ebiom.2016.08.043>

Scott, R. A., Scott, L. J., Mägi, R., Marullo, L., Gaulton, K. J., Kaakinen, M., Pervjakova, N., Pers, T. H., Johnson, A. D., Eicher, J. D., Jackson, A. U., Ferreira, T., Lee, Y., Ma, C., Steinthorsdottir, V., Thorleifsson, G., Qi, L., Van Zuydam, N. R., Mahajan, A., Chen, H., ... DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium (2017). An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. *Diabetes*, 66(11), 2888–2902. <https://doi.org/10.2337/db16-1253>

Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J. D., Cooper-Smith, C. M., Hotchkiss, R. S., Levy, M. M., Marshall, J. C., Martin, G. S., Opal, S. M., Rubenfeld, G. D., van der Poll, T., Vincent, J. L., & Angus, D. C. (2016). The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*, 315(8), 801–810. <https://doi.org/10.1001/jama.2016.0287>

Sørensen, T. I., Nielsen, G. G., Andersen, P. K., & Teasdale, T. W. (1988). Genetic and environmental influences on premature death in adult adoptees. *The New England journal of medicine*, 318(12), 727–732. <https://doi.org/10.1056/NEJM198803243181202>

Srinivasan, L., Page, G., Kirpalani, H., Murray, J. C., Das, A., Higgins, R. D., Carlo, W. A.,

Bell, E. F., Goldberg, R. N., Schibler, K., Sood, B. G., Stevenson, D. K., Stoll, B. J., Van Meurs, K. P., Johnson, K. J., Levy, J., McDonald, S. A., Zaterka-Baxter, K. M., Kennedy, K. A., Sánchez, P. J., ... Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (2017). Genome-wide association study of sepsis in extremely premature infants. *Archives of disease in childhood. Fetal and neonatal edition*, 102(5), F439–F445. <https://doi.org/10.1136/archdischild-2016-311545>

Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., Liu, B., Matthews, P., Ong, G., Pell, J., Silman, A., Young, A., Sprosen, T., Peakman, T., & Collins, R. (2015). UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine*, 12(3), e1001779. <https://doi.org/10.1371/journal.pmed.1001779>

van Beest, P. A., Hofstra, J. J., Schultz, M. J., Boerma, E. C., Spronk, P. E., & Kuiper, M. A. (2008). The incidence of low venous oxygen saturation on admission to the intensive care unit: a multi-center observational study in The Netherlands. *Critical care*, 12(2), R33. <https://doi.org/10.1186/cc681>

Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., Joyce, C., Li, Q., McArthur, C., Perner, A., Rhodes, A., Thompson, K., Webb, S., Myburgh, J., & ADRENAL Trial Investigators and the Australian–New Zealand Intensive Care Society Clinical Trials Group (2018). Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. *The New England journal of medicine*, 378(9), 797–808. <https://doi.org/10.1056/NEJMoa1705835>

Wang, H. E., Shapiro, N. I., Griffin, R., Safford, M. M., Judd, S., & Howard, G. (2012). Chronic medical conditions and risk of sepsis. *PloS one*, 7(10), e48307. <https://doi.org/10.1371/journal.pone.0048307>



Yengo, L., Sidorenko, J., Kemper, K. E., Zheng, Z., Wood, A. R., Weedon, M. N., Frayling, T. M., Hirschhorn, J., Yang, J., Visscher, P. M., & GIANT Consortium (2018). Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Human molecular genetics*, 27(20), 3641–3649. <https://doi.org/10.1093/hmg/ddy271>

Zheng, J., Erzurumluoglu, A. M., Elsworth, B. L., Kemp, J. P., Howe, L., Haycock, P. C., Hemani, G., Tansey, K., Laurin, C., Early Genetics and Lifecourse Epidemiology (EAGLE) Eczema Consortium, Pourcain, B. S., Warrington, N. M., Finucane, H. K., Price, A. L., Bulik-Sullivan, B. K., Anttila, V., Paternoster, L., Gaunt, T. R., Evans, D. M., & Neale, B. M. (2017). LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics*, 33(2), 272–279. <https://doi.org/10.1093/bioinformatics/btw613>

## **List of abbreviations**

**ADRENAL-GWAS:** ADRENAL Genome-Wide Association Study

**CRP:** C-Reactive Protein

**CTG-VL:** Complex-Traits Genetics Virtual Lab

**DBP:** Diastolic Blood Pressure

**DEPICT:** Data-Driven Expression-Prioritized Integration for Complex Traits

**GWAS:** Genome-Wide Association Study

**HWE:** Hardy Weinberg Equilibrium

**MAF:** Minor Allele Frequency

**PC:** Principal Component

**PRS:** Polygenic Risk Score

**QC:** Quality Control

**QIMRB:** QIMR Berghofer Medical Research Institute

**RR:** Relative Risk

**SNP:** Single Nucleotide Polymorphism

**T2D:** Type-2 Diabetes

**UKBB:** UK Biobank

**WBC:** White Blood Cell Count

**Table 1. Characteristics of ADRENAL-GWAS Patients Prior to Randomisation and Administration of Corticosteroids, and QIMRB Controls.**

| <b>Outcome</b>                            |                          |                                       |                                   | <b>Total (n)</b>        |
|---|--------------------------|---------------------------------------|-----------------------------------|-------------------------|
| Septic shock*                             |                          | 493 cases                             | 2442 controls                     | 2935                    |
| 90-day mortality                          |                          | 112 non-survivors                     | 381 survivors                     | 493                     |
| 28-day mortality                          |                          | 90 non-survivors                      | 403 survivors                     | 493                     |
| Shock resolution                          |                          | 459 resolved                          | 34 unresolved                     | 493                     |
| <b>Dichotomous Characteristics</b>        | <b>Overall Ratio (%)</b> | <b>90-Day Non-Survivors Ratio (%)</b> | <b>90-Day Survivors Ratio (%)</b> | <b>P-Value</b>          |
| Treatment(steroid/placebo)                | 265/493 (53.75%)         | 65/112 (58.04%)                       | 200/381 (52.49%)                  | 0.35                    |
| Re-admission (yes/no)                     | 108/492 † (21.95%)       | 29/112 (25.89%)                       | 79/380 (20.79%)                   | 0.27                    |
| Sex (female/male)                         | 183/493 (37.11%)         | 45/112 (40.18%)                       | 138/381 (36.22%)                  | 0.52                    |
| Use of renal replacement therapy (yes/no) | 141/491 (28.72%)         | 55/111 (49.55%)                       | 86/380 (22.63%)                   | 6.85 x 10 <sup>-8</sup> |
| Bacteraemia (yes/no)                      | 75/490 (15.31%)          | 10/111 (9.01%)                        | 65/379 (17.15%)                   | 0.05                    |
| <b>Quantitative Characteristics</b>       | <b>Overall Mean (%)</b>  | <b>90-Day Non-Survivors Mean (SD)</b> | <b>90-Day Survivors Mean (SD)</b> | <b>P-Value</b>          |
| Age (years)                               | 63.80 (14.72)            | 69.67 (12.85)                         | 62.08 (14.78)                     | 3.18 x 10 <sup>-7</sup> |
| APACHE (II) score                         | 23.28 (6.97)             | 26.30 (7.37)                          | 22.39 (6.59)                      | 1.26 x 10 <sup>-6</sup> |
| Weight (kg)                               | 89.72 (29.04)            | 87.93 (31.24)                         | 90.25 (28.33)                     | 0.48                    |
| Time to resolution of shock (days)        | 4.55 (5.12)              | 5.54 (5.66)                           | 3.88 (4.89)                       | 5.52 x 10 <sup>-3</sup> |
| Base temperature (°C)                     | 37.31 (1.02)             | 36.96 (1.04)                          | 37.41 (0.99)                      | 8.98 x 10 <sup>-5</sup> |
| Base heart rate (bpm)                     | 91.26 (20.04)            | 92.54 (19.37)                         | 92.18 (20.24)                     | 0.87                    |
| Base central venous pressure (mm Hg)      | 12.20 (5.72)             | 13.43 (6.67)                          | 11.84 (5.36)                      | 0.06                    |
| Lowest mean arterial pressure (mm Hg)     | 58.13 (7.87)             | 57.88 (9.10)                          | 58.21 (7.47)                      | 0.72                    |
| Lowest Pa <sub>2</sub> :F <sub>2</sub>    | 165.23 (86.11)           | 155.03 (82.37)                        | 168.20 (86.95)                    | 0.15                    |
| Highest arterial lactate (mg/dl)          | 3.39 (2.66)              | 4.55 (3.07)                           | 3.06 (2.43)                       | 6.21 x 10 <sup>-6</sup> |
| Highest bilirubin (mg/dl)                 | 31.49 (38.85)            | 45.01 (59.59)                         | 27.51 (28.95)                     | 3.48 x 10 <sup>-3</sup> |
| Highest creatinine (mg/dl)                | 174.05                   | 191.77 (140.68)                       | 168.83 (136.68)                   | 0.13                    |

|  |                    |                     |                 |                         |
|--|--------------------|---------------------|-----------------|-------------------------|
|  | (137.94)           |                     |                 |                         |
| Lowest haemoglobin (g/L)                         | 104.44<br>(22.84)  | 101.91 (23.75)      | 105.18 (22.52)  | 0.20                    |
| Highest white cells (cells x 10 <sup>9</sup> /L) | 17.08<br>(10.69)   | 16.75 (9.58)        | 17.17 (10.99)   | 0.69                    |
| Lowest platelet count (x 10 <sup>9</sup> /L)     | 211.88<br>(121.20) | 187.121<br>(118.98) | 219.14 (120.89) | 0.01                    |
| Highest international normalised ratio           | 1.65 (0.83)        | 1.93 (0.97)         | 1.56 (0.76)     | 5.95 x 10 <sup>-4</sup> |

Reported is the ratio and percentage for dichotomous characteristics, and the mean and standard deviation (SD) for quantitative traits. Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II assess the severity of disease, ranging between 0 (low risk for death) and 71 (high risk). A Student's *t*-test was used to test for differences in the mean quantitative traits between 90-day survivors and non-survivors. A Chi-squared Test of Independence was used to test for difference in dichotomous traits between 90-day survivors and non-survivors. \* The susceptibility to septic shock analyses were the only analyses containing QIMRB controls. † There was some missing data.

**Table 2. Lead SNPs with P-Value < 1 x 10<sup>-6</sup> from the Genome-Wide Association Studies (GWAS).**

| <b>GWAS Phenotype</b> | <b>SNP</b> | <b>Chromosome: Base Pair Position</b> | <b>Variant Type</b>           | <b>MA F</b> | <b>Effect / Non-effect Allele</b> | <b>Odds Ratio (SE)</b> | <b>P-Value</b>            |
|-----------------------|------------|---------------------------------------|-------------------------------|-------------|-----------------------------------|------------------------|---------------------------|
| Septic shock          | rs9489328  | 6:98104575                            | Intronic<br><i>AL589740.1</i> | 0.10        | T/G                               | 0.37 (0.15)            | *1.05 x 10 <sup>-10</sup> |
| Shock resolution      | rs11167801 | 5:142470334                           | Intronic<br><i>ARHGAP26</i>   | 0.09        | T/C                               | 0.13 (0.39)            | 8.77 x 10 <sup>-8</sup>   |
| 28-day mortality      | rs368584   | 13:111145073                          | Intronic<br><i>COL4A2</i>     | 0.39        | G/C                               | 2.56 (0.18)            | 2.55 x 10 <sup>-7</sup>   |
| Shock resolution      | rs7698838  | 4:58088682                            | Intergenic                    | 0.07        | C/T                               | 0.15 (0.38)            | 6.11 x 10 <sup>-7</sup>   |
| Shock resolution      | rs17128291 | 14:92882826                           | Intronic<br><i>SLC24A4</i>    | 0.18        | G/A                               | 0.22 (0.30)            | 7.48 x 10 <sup>-7</sup>   |

Lead single nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) < 5% were removed. The MAF, odds ratio, and standard error (SE) correspond to the minor allele. The hg38 human genome build was used. \* indicates genome-wide significance

**Table 3. FastBAT Results for the Outcomes (A) Susceptibility to Septic shock, (B) 28-Day Mortality, (C) 90-Day Mortality, and (D) Shock Resolution.**

|    | Gene            | # of SNPs | P-Value                 | Top SNP     | Top SNP P-Value         | Gene Ontology Annotations  | Genome-Wide Significant GWAS Catalog Associations                           |
|----|-----------------|-----------|-------------------------|-------------|-------------------------|--|---|
| A) | <i>IPO5</i>     | 154       | 5.06 x 10 <sup>-5</sup> | rs34511977  | 2.76 x 10 <sup>-6</sup> | Protein transporter activity   | -   |
|    | <i>KLB</i>      | 142       | 1.90 x 10 <sup>-4</sup> | rs7685429   | 5.60 x 10 <sup>-5</sup> | Hydrolase activity, hydrolyzing O-glycosyl compounds, fibroblast growth factor binding | Alcohol consumption, blood urea nitrogen levels, pulse pressure             |
|    | <i>IPO8</i>     | 73        | 2.91 x 10 <sup>-4</sup> | rs10771759  | 2.39x10 <sup>-5</sup>   | GTPase binding, protein import into nucleus  | Vital capacity, height, initial pursuit acceleration in psychotic disorders |
|    | <i>C9orf106</i> | 128       | 2.96 x 10 <sup>-4</sup> | rs117016656 | 1.80 x 10 <sup>-4</sup> | -  | -   |
|    | <i>CMTM7</i>    | 219       | 3.12 x 10 <sup>-4</sup> | rs6550132   | 4.53 x 10 <sup>-4</sup> | Cytokine activity, B-1a B cell differentiation, chemotaxis, signal transduction        | IgM levels, adolescent idiopathic scoliosis                                 |
| B) | <i>RAB20</i>    | 240       | 2.18 x 10 <sup>-4</sup> | rs368584    | 2.55 x 10 <sup>-7</sup> | GTPase activity, endosome  | Acute myeloid leukemia, hair colour   |
|    | <i>MIR1909</i>  | 107       | 3.98 x 10 <sup>-4</sup> | rs35202074  | 6.16 x 10 <sup>-5</sup> | -  | -   |
|    | <i>KTNI-AS1</i> | 68        | 5.26 x 10 <sup>-4</sup> | rs10145555  | 8.78 x 10 <sup>-5</sup> | -  | Putamen volume  |
|    | <i>COL4A2-</i>  | 228       | 6.15 x                  | rs368584    | 2.55 x                  | -  | -   |

|    |                  |     |                       |            |                       |  |   |
|----|------------------|-----|-----------------------|------------|-----------------------|--|---|
|    | <i>ASI</i>       |     | $10^{-4}$             |            | $10^{-7}$             |  |   |
|    | <i>NINJ2</i>     | 339 | $7.15 \times 10^{-4}$ | rs35557779 | $6.21 \times 10^{-5}$ | Integral component of plasma membrane, neuron cell-cell adhesion, tissue regeneration, nervous system development        | Platelet distribution width, platelet count, plateletcrit, lymphocyte counts, granulocyte percentage of myeloid white cells, stroke, monocyte count, monocyte percentage of white cells, white blood cell count |
| C) | <i>BRSK1</i>     | 161 | $7.64 \times 10^{-5}$ | rs10403600 | $6.49 \times 10^{-5}$ | Magnesium ion binding, protein kinase activity, protein serine/threonine kinase activity                                 | Age at menopause, age at menarche   |
|    | <i>TMEM150 B</i> | 156 | $2.34 \times 10^{-4}$ | rs10403600 | $6.49 \times 10^{-5}$ | Autophagy, regulation of autophagy,  | Age at menopause, unipolar depression   |
|    | <i>NMURI</i>     | 79  | $3.29 \times 10^{-4}$ | rs72989550 | $5.08 \times 10^{-5}$ | Neuromedin U receptor activity, G protein-coupled receptor activity  | Height  |
|    | <i>HSPBP1</i>    | 152 | $3.44 \times 10^{-4}$ | rs10403600 | $6.49 \times 10^{-5}$ | Adenyl-nucleotide exchange factor activity, enzyme inhibitor activity, protein binding, ubiquitin protein ligase binding | -   |
|    | <i>NINJ2</i>     | 340 | $4.84 \times 10^{-4}$ | rs10849390 | $9.75 \times 10^{-5}$ | Integral component of plasma membrane, neuron cell-cell adhesion, tissue regeneration, nervous system development        | Platelet distribution width, platelet count, plateletcrit, lymphocyte counts, granulocyte percentage of myeloid white cells, stroke, monocyte count, monocyte percentage of white cells, white blood cell count |
| D) | <i>SSI8</i>      | 71  | $3.63 \times 10^{-5}$ | rs765529   | $3.32 \times 10^{-6}$ | Transcription coactivator activity, protein binding, nuclear receptor transcription                                      | Red blood cell distribution width, mean corpuscular haemoglobin   |

|                |     |                            |            |                            |  |  |  |
|----------------|-----|----------------------------|------------|----------------------------|--|--|--|
|                |     |                            |            |                            |  | coactivator activity   |  |
| <i>PSMA8</i>   | 84  | 3.71 x<br>10 <sup>-5</sup> | rs9304490  | 4.20 x<br>10 <sup>-6</sup> |  | Antigen processing and presentation of exogenous peptide antigen via HLA, MAPK cascade, protein polyubiquitiation, stimulatory C-type lectin receptor signalling pathway | -  |
| <i>SLC24A4</i> | 383 | 2.79 x<br>10 <sup>-4</sup> | rs17128291 | 7.48 x<br>10 <sup>-7</sup> |  | Calcium channel activity, symporter activity, antiporter activity  | Hair colour, eye colour, suntan, Alzheimer's disease |
| <i>MIR4282</i> | 58  | 5.06 x<br>10 <sup>-4</sup> | rs12664923 | 3.33 x<br>10 <sup>-5</sup> |  | -  | -  |
| <i>NANS</i>    | 82  | 7.37 x<br>10 <sup>-4</sup> | rs4412474  | 3.04 x<br>10 <sup>-4</sup> |  | CMP-N-acetylneuraminate biosynthetic process, carbohydrate biosynthetic process  | -  |

The top five genes associated with the primary outcomes are tabulated, along with the number of single nucleotide polymorphisms (SNPs) within the gene region, the gene-based test p-value, the most significant SNP within the region, and the respective p-value from the genome-wide association study (GWAS), interesting gene ontology annotations, and previous associations listed within the GWAS Catalog (MacArthur et al., 2017). The FastBAT analyses were carried out using the Complex-Traits Genetics Virtual Lab (Bakshi et al., 2016; Cuéllar-Partida et al., 2019).



**Table 4. Polygenic Risk Score (PRS) Analysis Results.**

| GWAS Phenotype                             | P-Value Threshold         | N SNPs | Septic Shock |                               | 28-Day Mortality |                               |
|--|---------------------------|--------|--------------|-------------------------------|------------------|-------------------------------|
|  |                           |        | Direction    | P-Value                       | Direction        | P-Value                       |
| C-Reactive Protein levels                  | < 1                       | 267725 | +            | <b>2.23 x 10<sup>-3</sup></b> | -                | 2.78 x 10 <sup>-1</sup>       |
|  | < 0.5                     | 202435 | +            | <b>1.44 x 10<sup>-3</sup></b> | -                | 3.02 x 10 <sup>-1</sup>       |
|  | < 0.01                    | 13767  | +            | 2.22 x 10 <sup>-2</sup>       | +                | 8.53 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-6</sup> | 330    | +            | 3.90 x 10 <sup>-1</sup>       | +                | 1.48 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-8</sup> | 167    | -            | 9.79 x 10 <sup>-1</sup>       | +                | 1.16 x 10 <sup>-1</sup>       |
| Granulocyte Count                          | < 1                       | 334324 | +            | 5.89 x 10 <sup>-1</sup>       | -                | <b>2.29 x 10<sup>-3</sup></b> |
|  | < 0.5                     | 244497 | +            | 5.29 x 10 <sup>-1</sup>       | -                | <b>2.61 x 10<sup>-3</sup></b> |
|  | < 0.01                    | 15157  | +            | 8.08 x 10 <sup>-1</sup>       | -                | 1.07 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-6</sup> | 698    | +            | 9.16 x 10 <sup>-1</sup>       | -                | 2.31 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-8</sup> | 379    | -            | 8.11 x 10 <sup>-1</sup>       | -                | 4.40 x 10 <sup>-1</sup>       |
| Diastolic Blood Pressure Automated Reading | < 1                       | 320701 | -            | 7.22 x 10 <sup>-2</sup>       | -                | 7.97 x 10 <sup>-1</sup>       |
|  | < 0.5                     | 242169 | -            | 3.70 x 10 <sup>-2</sup>       | -                | 6.33 x 10 <sup>-1</sup>       |
|  | < 0.01                    | 21859  | -            | 2.69 x 10 <sup>-2</sup>       | +                | 2.84 x 10 <sup>-2</sup>       |
|  | < 5.00 x 10 <sup>-6</sup> | 806    | -            | 2.41 x 10 <sup>-2</sup>       | -                | 9.84 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-8</sup> | 308    | -            | 3.51 x 10 <sup>-1</sup>       | -                | 7.48 x 10 <sup>-1</sup>       |
| Hematocrit                                 | < 1                       | 334250 | -            | 9.12 x 10 <sup>-1</sup>       | -                | <b>3.04 x 10<sup>-3</sup></b> |
|  | < 0.5                     | 244826 | +            | 9.54 x 10 <sup>-1</sup>       | -                | <b>4.27 x 10<sup>-3</sup></b> |
|  | < 0.01                    | 15278  | +            | 8.05 x 10 <sup>-1</sup>       | -                | 1.28 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-6</sup> | 621    | -            | 5.52 x 10 <sup>-1</sup>       | -                | 3.80 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-8</sup> | 306    | -            | 9.34 x 10 <sup>-1</sup>       | -                | 3.57 x 10 <sup>-1</sup>       |
| White Blood Cell Count                     | < 1                       | 333971 | +            | 2.76 x 10 <sup>-1</sup>       | -                | 4.20 x 10 <sup>-1</sup>       |
|  | < 0.5                     | 244165 | +            | 2.24 x 10 <sup>-1</sup>       | -                | 4.05 x 10 <sup>-1</sup>       |
|  | < 0.01                    | 15586  | +            | 9.86 x 10 <sup>-2</sup>       | -                | 4.91 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-6</sup> | 808    | +            | 6.68 x 10 <sup>-1</sup>       | +                | 7.14 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-8</sup> | 453    | +            | 7.57 x 10 <sup>-1</sup>       | +                | 8.33 x 10 <sup>-1</sup>       |
| Coronary Artery Disease                    | < 1                       | 122441 | -            | 1.85 x 10 <sup>-1</sup>       | -                | 1.79 x 10 <sup>-1</sup>       |
|  | < 0.5                     | 93427  | -            | 1.55 x 10 <sup>-1</sup>       | -                | 2.27 x 10 <sup>-1</sup>       |
|  | < 0.01                    | 6784   | -            | 3.54 x 10 <sup>-1</sup>       | -                | 3.63 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-6</sup> | 57     | -            | 8.67 x 10 <sup>-1</sup>       | -                | 9.34 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-8</sup> | 20     | -            | 9.69 x 10 <sup>-1</sup>       | -                | 2.28 x 10 <sup>-1</sup>       |
| Type 2 Diabetes                            | < 1                       | 341453 | -            | 9.66 x 10 <sup>-1</sup>       | -                | 9.83 x 10 <sup>-1</sup>       |
|  | < 0.5                     | 252082 | -            | 8.15 x 10 <sup>-1</sup>       | +                | 9.33 x 10 <sup>-1</sup>       |
|  | < 0.01                    | 19284  | -            | 7.26 x 10 <sup>-1</sup>       | +                | 6.10 x 10 <sup>-1</sup>       |
|  | < 5.00 x 10 <sup>-6</sup> | 660    | -            | 2.27 x 10 <sup>-1</sup>       | +                | 4.48 x 10 <sup>-1</sup>       |

|                                    |                         |        |   |                       |   |                       |
|------------------------------------|-------------------------|--------|---|-----------------------|---|-----------------------|
|                                    | $< 5.00 \times 10^{-8}$ | 315    | - | $1.80 \times 10^{-1}$ | + | $7.77 \times 10^{-1}$ |
| Septicaemia/Sepsis<br>(UK Biobank) | $< 1$                   | 321265 | + | $1.94 \times 10^{-1}$ | + | $2.84 \times 10^{-1}$ |
|                                    | $< 0.5$                 | 235509 | + | $1.71 \times 10^{-1}$ | + | $2.38 \times 10^{-1}$ |
|                                    | $< 0.01$                | 11267  | - | $9.80 \times 10^{-1}$ | + | $1.01 \times 10^{-1}$ |
|                                    | $< 5.00 \times 10^{-6}$ | 60     | + | $2.02 \times 10^{-1}$ | + | $5.91 \times 10^{-1}$ |
|                                    | $< 5.00 \times 10^{-8}$ | 5      | + | $8.76 \times 10^{-1}$ | - | $5.15 \times 10^{-1}$ |
| Other Septicaemia<br>(UK Biobank)  | $< 1$                   | 321253 | + | $6.90 \times 10^{-1}$ | + | $5.60 \times 10^{-1}$ |
|                                    | $< 0.5$                 | 235757 | + | $7.10 \times 10^{-1}$ | + | $5.79 \times 10^{-1}$ |
|                                    | $< 0.01$                | 11346  | + | $2.89 \times 10^{-2}$ | + | $3.42 \times 10^{-1}$ |
|                                    | $< 5.00 \times 10^{-6}$ | 19     | - | $6.72 \times 10^{-1}$ | - | $8.10 \times 10^{-1}$ |
|                                    | $< 5.00 \times 10^{-8}$ | 3      | - | $3.41 \times 10^{-1}$ | + | $5.41 \times 10^{-1}$ |
| Height                             | $< 1$                   | 124453 | + | $7.07 \times 10^{-2}$ | + | $4.90 \times 10^{-1}$ |
|                                    | $< 0.5$                 | 102079 | - | $7.14 \times 10^{-2}$ | + | $4.95 \times 10^{-1}$ |
|                                    | $< 0.01$                | 29680  | - | $2.51 \times 10^{-1}$ | + | $6.43 \times 10^{-1}$ |
|                                    | $< 5.00 \times 10^{-6}$ | 8442   | - | $7.26 \times 10^{-1}$ | - | $8.61 \times 10^{-1}$ |
|                                    | $< 5.00 \times 10^{-8}$ | 5416   | - | $7.87 \times 10^{-1}$ | + | $9.80 \times 10^{-1}$ |

Septic shock patients (ADRENAL-GWAS) and population controls (QIMRB) were scored on their genotypes at single nucleotide polymorphisms (SNPs; weighted by the reported effect sizes) that reached various p-value thresholds ( $< 5 \times 10^{-8}$ ,  $5 \times 10^{-6}$ , 0.01, 0.5, and 1) in nine genome-wide association studies (GWAS) for traits of interest. The number of SNPs (N SNPs) included in each analysis is tabulated. Regressions for septic shock and 28-day mortality were performed, with standardised PRS as a predictor, and the top five principal components as covariates (as well as age and sex for 28-day mortality). The direction of the beta coefficient is noted, where a positive coefficient indicates a positive association with the tested phenotype (i.e. increased propensity to septic shock and/or increased risk of mortality at 28 days), and vice-versa for negative coefficients. Bolded p-values indicate statistically significant results after Bonferroni correction for multiple testing ( $p \leq 5 \times 10^{-3}$ ).

## **Acknowledgments**

We thank participants and their families for their contributions and ongoing support of research. The authors acknowledge the extensive work carried out by current and former QIMRB staff, particularly the current QIMRB Sample Processing facility (formerly Molecular Epidemiology lab) for sample processing; former interviewers, IT, and project staff for recruitment and data collection; and the use of the QIMRB High Performance Computing facility for data storage and analysis. We thank the NHMRC for funding that supported the genotyping of QIMRB controls (grants NHMRC APP1031119 and APP1084325).

## **Financial Support**

This work was supported by an NHMRC project grant (GNT1085159 to DME, BV, SF, JM, and JC). DME is supported by an NHMRC Senior Research Fellowship (APP1137714). JP is supported by a NHMRC Career Development Fellowship (APP1107599). SD received a University of Queensland Diamantina Honours scholarship. SEM is supported by an NHMRC Senior Research Fellowship (APP1103623). JM is supported by a Level 2 NHMRC Practitioner Fellowship. BV is supported by a MRFF Practitioner Fellowship. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

## **Conflict of Interest**

We declare no competing interests.

## **Ethical standards**

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

## **Author Contributions**

DME, MAB, BV, JM, SF, JP, and JC conceived the study. JM, SF, JC, and BV oversaw the clinical trial, and nurses at the various hospital sites collected the data. EP, DR, BV, DE and JC managed the ADRENAL-GWAS subset of the project. MAB and EDG performed the ADRENAL-GWAS genotyping. SEM, SDG, and NGM were involved in sample preparation of the control cohort. SD and GCP cleaned the data and performed the statistical analyses. SD performed the literature search and prepared all tables and figures. The CHARGE Inflammation Working group and SL managed and provided C-reactive protein analyses and aided in interpretation of the results alongside DME, GCP, AB, BV, JC and SD. DME, GCP, and AB supervised the work. SD prepared the manuscript for submission. All authors reviewed the article and approved the final version